1. Home
  2. NEM vs SNY Comparison

NEM vs SNY Comparison

Compare NEM & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Newmont Corporation

NEM

Newmont Corporation

N/A

Current Price

$114.33

Market Cap

138.7B

ML Signal

N/A

Logo Sanofi ADS

SNY

Sanofi ADS

N/A

Current Price

$43.69

Market Cap

116.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NEM
SNY
Founded
1916
1994
Country
United States
France
Employees
17500
74846
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
138.7B
116.8B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NEM
SNY
Price
$114.33
$43.69
Analyst Decision
Strong Buy
Buy
Analyst Count
10
6
Target Price
$113.50
$61.50
AVG Volume (30 Days)
7.4M
4.1M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
0.89%
3.64%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$20.18
$3.01
Revenue Next Year
$4.04
$5.80
P/E Ratio
$19.39
$6.14
Revenue Growth
N/A
N/A
52 Week Low
$42.93
$43.51
52 Week High
$134.88
$59.17

Technical Indicators

Market Signals
Indicator
NEM
SNY
Relative Strength Index (RSI) 43.42 32.23
Support Level $108.05 N/A
Resistance Level $131.40 $48.97
Average True Range (ATR) 4.26 0.68
MACD -1.44 -0.36
Stochastic Oscillator 15.04 6.20

Price Performance

Historical Comparison
NEM
SNY

About NEM Newmont Corporation

Newmont is the world's largest gold miner. It bought Goldcorp in 2019, combined its Nevada mines in a joint venture with competitor Barrick later that year, and also purchased competitor Newcrest in November 2023. Its portfolio includes 11 mines and interests in two joint ventures in the Americas, Africa, Australia, and Papua New Guinea. The company is expected to sell roughly 5.6 million ounces of gold in 2025 from its core mines after selling six higher-cost, smaller mines following the Newcrest acquisition. Newmont also produces material amounts of copper, silver, zinc, and lead as byproducts. It had about two decades of gold reserves, along with significant byproduct reserves at the end of December 2024.

About SNY Sanofi ADS

Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

Share on Social Networks: